ReviewAnti-cancer agents in medicinal chemistry2011
FAK and p53 protein interactions.
Review in Anti-cancer agents in medicinal chemistry, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 48 citations in OpenAlex.
- Li-Fraumeni Syndrome: Narrative Review Through a Case Report with Ten Years of Primary Tumor Remission Associated withInternational journal of molecular sciences · 2024Review
- FAK Drives Resistance to Therapy in HPV-Negative Head and Neck Cancer in a p53-Dependent Manner.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- Early SRC activation skews cell fate from apoptosis to senescence.Science advances · 2022Article
- SY-707, an ALK/FAK/IGF1R inhibitor, suppresses growth and metastasis of breast cancer cells.Acta biochimica et biophysica Sinica · 2022Article
- Regulation of p53 Function by Formation of Non-Nuclear Heterologous Protein Complexes.Biomolecules · 2022Review
- Focal adhesion kinase plays a dual role in TRAIL resistance and metastatic outgrowth of malignant melanoma.Cell death & disease · 2022Article
- Functional and clinical characteristics of focal adhesion kinases in cancer progression.Frontiers in cell and developmental biology · 2022Review
- FAK inhibitors as promising anticancer targets: present and future directions.Future medicinal chemistry · 2021Review
- Identification of p53 Activators in a Human Microarray Compendium.Chemical research in toxicology · 2019Article
- p53-inducible gene 3 promotes cell migration and invasion by activating the FAK/Src pathway in lung adenocarcinoma.Cancer science · 2018Article
- Anti-invasive effects of CXCR4 and FAK inhibitors in non-small cell lung carcinomas with mutually inactivated p53 and PTEN tumor suppressors.Investigational new drugs · 2017Article
- Review
- Focal Adhesion Kinase: Insight into Molecular Roles and Functions in Hepatocellular Carcinoma.International journal of molecular sciences · 2017Review
- Integrin and FAK Regulation of Human Pluripotent Stem Cells.Current stem cell reports · 2017Review
- Signal-Oriented Pathway Analyses Reveal a Signaling Complex as a Synthetic Lethal Target for p53 Mutations.Cancer research · 2016Article
- The physical interaction of p53 and plakoglobin is necessary for their synergistic inhibition of migration and invasion.Oncotarget · 2016Article
- Podocyte p53 Limits the Severity of Experimental Alport Syndrome.Journal of the American Society of Nephrology : JASN · 2016Article
- β1 Integrins as Therapeutic Targets to Disrupt Hallmarks of Cancer.Frontiers in pharmacology · 2015Review
- The extracellular matrix modulates the hallmarks of cancer.EMBO reports · 2014Review
- NANOG: a promising target for digestive malignant tumors.World journal of gastroenterology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Focal Adhesion Kinase plays a major role in cell adhesion, motility, survival, proliferation, metastasis, angiogenesis and lymphangiogenesis. In 2004, we have cloned the promoter sequence of FAK and found that p53 inhibits its activity (BBA, v. 1678, 2004). In 2005, we were the first group to show that FAK and p53 proteins directly interact in the cells (JBC, v. 280, 2005). We have shown that FAK and p53 proteins interact in the cytoplasm and in the nucleus by immunoprecipitation, pull-down and confocal microscopy assays. We have shown that FAK inhibited activity of p53 with the transcriptional targets: p21, Bax and Mdm-2 through protein-protein interactions. We identified the 7 amino-acid site in p53 that is involved in interaction with FAK protein. The present review will discuss the interaction of FAK and p53 proteins and discuss the mechanism of FAK-p53 loop regulation: inhibition of FAK promoter activity by p53 protein and also inhibition of p53 transcriptional activity by FAK protein.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.